CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced the completion of its previously announced underwritten public offering of 3,450,000 shares of its common stock at a price of $9.00 per share for gross proceeds of approximately $31 million. The aggregate number of shares sold reflects the exercise in full by the underwriters of their over-allotment option to purchase an additional 450,000 shares of common stock. The Company received net proceeds of approximately $29 million, after deducting underwriting discounts and commissions and estimated offering expenses. Jefferies & Company and Thomas Weisel Partners LLC served as the underwriters for this offering.
